Logotype for BASF SE

BASF (BAS) Q3 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for BASF SE

Q3 2024 earnings summary

18 Jan, 2026

Executive summary

  • Q3 2024 sales were €15.7 billion, flat year-over-year, with group volumes up 7% excluding metals and strong core business performance offset by currency headwinds and lower prices.

  • EBITDA before special items rose 5% to €1.62 billion, driven by higher volumes and margins in core businesses.

  • Net income improved to €287 million from a loss of €249 million in Q3 2023, aided by a €389 million disposal gain from the Wintershall Dea asset transfer.

  • Cost savings programs are progressing, achieving an €800 million run rate by Q3, with a target of €2.1 billion annual savings by 2026.

  • Significant events included the closure of glufosinate-ammonium production, a fire at Ludwigshafen, further plant closures in Germany, and the completion of the Wintershall Dea E&P business sale.

Financial highlights

  • EBITDA margin before special items increased to 10.3% from 9.8% year-over-year.

  • EBIT before special items was €635 million, up 10% year-over-year; EBIT fell 36.5% to €250 million.

  • Free cash flow declined to €569 million from €1.5 billion in Q3 2023, mainly due to lower cash inflows from net working capital.

  • Net debt rose to €19.7 billion, with a solid equity ratio of 45.4%.

  • Credit ratings remain strong (S&P A-, Moody's A3, Fitch A).

Outlook and guidance

  • 2024 guidance unchanged: EBITDA before special items €8.0–8.6 billion, free cash flow €0.1–0.6 billion, with expectations to reach the low end of the range.

  • New 2028 targets: EBITDA before special items €10–12 billion, cumulative free cash flow >€12 billion (2025–2028), ROCE ~10%.

  • Dividend policy: at least €2.25/share annually, with total shareholder distribution of €12 billion (2025–2028), including buybacks from 2027.

  • Q4 is expected to be challenging, with continued headwinds in automotive and agricultural sectors, significant FX impacts, and force majeure in nutrition and health impacting H2 EBITDA.

  • Risks for Q4 include potential price declines and lower volume growth; opportunities from improved demand and margins.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more